Envestnet Asset Management Inc. Has $4.90 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)

Envestnet Asset Management Inc. grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 33.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,247 shares of the pharmaceutical company’s stock after buying an additional 8,088 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $4,901,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its position in Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after buying an additional 132 shares in the last quarter. FNY Partners Fund LP lifted its position in Vertex Pharmaceuticals by 900.0% during the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after buying an additional 900 shares in the last quarter. Smithfield Trust Co. bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $135,000. FNY Managed Accounts LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $162,000. Finally, Dupont Capital Management Corp bought a new stake in Vertex Pharmaceuticals during the 2nd quarter worth about $186,000. 93.33% of the stock is currently owned by hedge funds and other institutional investors.

In related news, COO Ian F. Smith sold 2,125 shares of the company’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $155.61, for a total value of $330,671.25. Following the transaction, the chief operating officer now owns 118,013 shares in the company, valued at approximately $18,364,002.93. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 218,519 shares of company stock worth $31,819,910. 1.80% of the stock is owned by company insiders.

VRTX has been the topic of several analyst reports. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Vetr cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target on the stock. in a research report on Monday, September 4th. Royal Bank Of Canada upped their target price on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. HC Wainwright reaffirmed a “hold” rating and issued a $85.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $205.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $173.15.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $143.61 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $167.85. The company has a market cap of $35,097.85, a PE ratio of 231.30, a P/E/G ratio of 3.32 and a beta of 1.58. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same quarter in the prior year, the business earned $0.16 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 39.7% on a year-over-year basis. equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/12/10/envestnet-asset-management-inc-has-4-90-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply